Small Cell Lung Cancer (SCLC) Clinical Trials

Find Small Cell Lung Cancer (SCLC) Clinical Trials Near You

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions: an Italian Multicenter Retrospective Analysis (STRILL IT)

Status: Recruiting
Location: See all (11) locations...
Study Type: Observational
SUMMARY

Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation. When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after standard radiotherapy in some patients. However, there is very little information about using SBRT again in patients who already received SBRT the first time. Because only small studies have been done and the patients were very different from each other, doctors still do not know enough about how safe and effective a second SBRT treatment is. In particular, it is still unclear whether giving another high-dose radiation treatment is possible without causing serious side effects. More research is needed to better understand this option and help guide treatment decisions for patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Inoperable primary non-small cell lung cancer or other metastatic primaries with lung metastases, already treated with radical dose SBRT

• Inoperable local recurrence (defined as a tumor recurrence overlapping the 50% isodose field) confirmed by documented radiographic findings and/or pathological biopsies within the thoracic area

• Patients had previously received curative intent SBRT with a biologically equivalent dose equal or higher than 75 Gy

• Stereotactic reirradiation with ablative purposes up to 8 fractions

• No active distant metastasis or controlled distant metastasis at the time of re-irradiation

• More than 12 months from previous SBRT

• PS ≤ 2

Locations
Other Locations
Italy
AST Papa Giovanni XXIII
RECRUITING
Bergamo
Radiotherapy Department, Ospedale Bellaria Carlo Alberto Pizzardi
NOT_YET_RECRUITING
Bologna
REM Radioterapia
NOT_YET_RECRUITING
Catania
Radiation oncology unit, Ospedale San Raffaele
NOT_YET_RECRUITING
Milan
Radiotherapy Department, Istituto Europeo di Oncologia
NOT_YET_RECRUITING
Milan
Radiotherapy Department, IRCCS Istituto Nazionale Fondazione G. Pascale
NOT_YET_RECRUITING
Naples
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center
NOT_YET_RECRUITING
Negrar
Centro Fondazione Policlinico Universitario A. Gemelli, Radioterapia Oncologica
NOT_YET_RECRUITING
Roma
IRCCS Humanitas Research Hospital
RECRUITING
Rozzano
Radioterapia Oncologica - Ospedale dell'Angelo
NOT_YET_RECRUITING
Venezia
AOUI Verona, DAI Chirurgia e Oncologia - Radioterapia Oncologica
NOT_YET_RECRUITING
Verona
Contact Information
Primary
Davide Franceschini, MD, radiation oncologist
davide.franceschini@cancercenter.humanitas.it
+39 0282247428
Backup
Laura Bonavita, master degree
laura.bonavita@humanitas.it
+39 0282247026
Time Frame
Start Date: 2024-11-25
Estimated Completion Date: 2026-12
Participants
Target number of participants: 150
Treatments
re-irradiation SBRT
Patients treated with re-irradiation SBRT on non small cell lung carcinoma
Sponsors
Leads: Istituto Clinico Humanitas

This content was sourced from clinicaltrials.gov